On November 14, 2024, the T320-ADC antibody-drug conjugate, independently developed by Nanolattix Biotechnology, received official clinical trial approval from the Therapeutic Goods Administration (TGA), an agency under the Australian Department of Health. To date, T320 has been successfully submitted for approval and has received clearance in China, the United States, and Australia.

Australia enforces exceptionally strict regulations on the production and import of pharmaceuticals. The TGA certification is internationally recognized as one of the most rigorous regulatory frameworks for pharmaceutical products, known for its high barriers to market entry and esteemed global reputation. The official approval of the innovative anticancer drug T320 for clinical trials by the TGA represents a significant milestone for Nanolattix Biotechnology, highlighting its commitment to advancing a globalization strategy and driving the internationalization of this groundbreaking drug. T320, an innovative anticancer drug developed by Nanolattix Biotechnology, targets multiple malignant solid tumors and is designed to treat cervical cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, gastric cancer, and other conditions. It has demonstrated notable antitumor efficacy in preclinical studies and is now ready to advance into clinical development.

While deploying drugs for the treatment of cervical cancer, Nanolattix Biotechnology is also actively providing scientific and effective solutions for the prevention of cervical cancer. Nanolattix's "Dr.Clekon" can rapidly inactivate HPV, with a kill rate of up to 99.99%, providing a practical and effective product for cervical cancer prevention. Nanolattix Biotechnology adheres to the principle of emphasizing both prevention and treatment, safeguarding every aspect of women's health, and offering more affordable and effective treatment options for patients worldwide.

Source: Nanolattix Biotechnology